by mariel | Aug 12, 2025 | Portfolio News
Rapid Micro Biosystems entered into a five-year, $45 million term loan facility with $20 million funded at closing to strengthen financial flexibility. by mariel | Jul 16, 2025 | Portfolio News
Endeavor announced Orphan Drug Designation from both the European Commission and U.S. FDA for taladegib (ENV-101) for idiopathic pulmonary fibrosis; the company is enrolling WHISTLE-PF (Phase 2b).